All In Biotech

Drug Trial Radar · NCT01629966

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.

Last checked: Nov 20, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

680

Actual

Start

Jun 30, 2012

Primary completion

Feb 28, 2014

Study completion Mar 31, 2014

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Conditions

  • Generalized Anxiety Disorder

Interventions

  • PlaceboDrug

    Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,

  • VilazodoneDrug

    Vilazodone, 20mg, oral administration once per day.

  • VilazodoneDrug

    Vilazodone, 40mg, oral administration once per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreTime frame: Baseline to Week 8

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Forest Investigative Site 001

    Birmingham, Alabama

  • Forest Investigative Site 021

    Beverly Hills, California

  • Forest Investigative Site 023

    Glendale, California

  • Forest Investigative Site 011

    Paramount, California

  • Forest Investigative Site 026

    Norwich, Connecticut

  • Forest Investigative Site 027

    Waterbury, Connecticut

  • Forest Investigative Site 005

    Delray Beach, Florida

  • Forest Investigative Site 014

    Oakland Park, Florida

  • Forest Investigative Site 019

    South Miami, Florida

  • Forest Investigative Site 038

    Atlanta, Georgia

  • Forest Investigative Site 035

    Decatur, Georgia

  • Forest Investigative Site 028

    Chicago, Illinois

  • Forest Investigative Site 030

    Schaumburg, Illinois

  • Forest Investigative Site 029

    Topeka, Kansas

  • Forest Investigative Site 033

    Wichita, Kansas

  • Forest Investigative Site 010

    Lake Charles, Louisiana

  • Forest Investigative Site 031

    Baltimore, Maryland

  • Forest Investigative Site 025

    Boston, Massachusetts

  • Forest Investigative Site 037

    St Louis, Missouri

  • Forest Investigative Site 015

    Las Vegas, Nevada

  • Forest Investigative Site 016

    Berlin, New Jersey

  • Forest Investigative Site 007

    Brooklyn, New York

  • Forest Investigative Site 024

    New York, New York

  • Forest Investigative Site 032

    New York, New York

  • Forest Investigative Site 012

    New York, New York

  • Forest Investigative Site 020

    Bismarck, North Dakota

  • Forest Investigative Site 008

    Cincinnati, Ohio

  • Forest Investigative Site 041

    Dayton, Ohio

  • Forest Investigative Site 004

    Oklahoma City, Oklahoma

  • Forest Investigative Site 034

    Oklahoma City, Oklahoma

  • Forest Investigative Site 013

    Portland, Oregon

  • Forest Investigative Site 006

    Memphis, Tennessee

  • Forest Investigative Site 017

    Wichita Falls, Texas

  • Forest Investigative Site 003

    Salt Lake City, Utah

  • Forest Investigative Site 018

    Charlottesville, Virginia

  • Forest Investigative Site 040

    Bellevue, Washington

  • Forest Investigative Site 039

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.